Pathological Complete Response to Neoadjuvant Trastuzumab Is Dependent on HER2/CEP17 Ratio in HER2-Amplified Early Breast Cancer

Christian F. Singer, Michael Gnant, Florian Fitzal et al.|Clinical Cancer Research|2017

Cited by 61